Status:

UNKNOWN

Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of Persistent AF

Lead Sponsor:

Dignity Health Medical Foundation

Collaborating Sponsors:

Mercy General Hospital and Dignity Health Medical Foundation

Beth Israel Deaconess Medical Center

Conditions:

Persistent Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study it to learn whether pulmonary vein isolation (PVI) along with isolation of the posterior left atrial wall (PWI) in the region of the pulmonary venous component will reduce th...

Detailed Description

Patients with persistent atrial fibrillation will be enrolled in this multi-center, randomized, prospective, single-blinded study. After catheter ablation (isolation) of the pulmonary veins (PVI) and ...

Eligibility Criteria

Inclusion

  • Consistent with the current definitions, all patients with Persistent AF must exhibit an episode of continuous AF that is sustained \>7 days.
  • Patients must have symptomatic Persistent AF refractory or intolerant to at least one class I or class III antiarrhythmic drug
  • Males and females with an age \>18 years undergoing a first-time catheter ablation of AF; prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial flutter) is permitted
  • All patients must understand the requirements of the study and be willing to comply with the post-study follow-up requirements
  • Patients must have documented episode of AF greater than 7 days in the year prior to the procedure

Exclusion

  • History of long-standing persistent AF
  • Any reversible cause of AF (post-operative, thyroid disorder, etc.)
  • Patients with cerebral ischemic events (stroke or transient ischemic attack), myocardial infarction or unstable angina in the previous 2 months
  • Patients with any corrected or uncorrected congenital heart disease
  • Patients with a history of hypertrophic cardiomyopathy
  • Patients with cardiomyopathy and a left ventricular ejection fraction \<40%
  • Congestive heart failure, class IV
  • Left atrial (LA) diameter \>55 mm (parasternal long axis view)
  • Patients with left atrial thrombus
  • Women who are known to be pregnant or have had a positive β-HCG (human chorionic gonadotropin) test 7 days prior to procedure
  • Patients whose life expectancy is \<1 year
  • History of left-sided left atrial ablation (catheter or surgically-based)
  • Mental impairment precluding the patient from providing informed consent or completing appropriate follow-up

Key Trial Info

Start Date :

April 30 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2024

Estimated Enrollment :

153 Patients enrolled

Trial Details

Trial ID

NCT04505163

Start Date

April 30 2021

End Date

December 31 2024

Last Update

September 6 2023

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Mercy General Hospital and Dignity Health Medical Foundation

Sacramento, California, United States, 95819

2

UCHealth Medical Center

Fort Collins, Colorado, United States, 80528

3

MedStar Georgetown University Hospital and Medical Center

Washington D.C., District of Columbia, United States, 20007

4

Sarasota Memorial Health Care System

Sarasota, Florida, United States, 34239